Dubai Weekly
Cancer vaccines just moved from science headline to front-page market story after a US government push modeled on Operation Warp Speed sent Moderna up 9% in a single session and lifted peers like Pfizer, BioNTech and Merck. That kind of spotlight can reshape where capital flows next and who gets left behind. This article breaks down three US-listed cancer vaccine and immuno-oncology stocks exposed to this news and what that might mean for your watchlist.
The three stocks highlighted below are just a starter set from this theme. The full screen surfaced 36 more US-listed cancer vaccine and immuno-oncology companies with similarly detailed stories that are not covered here. To go deeper, analyze, compare, and identify your own highest-conviction ideas straight from the US-Listed Cancer Vaccine & Immuno-Oncology Innovators screener .
Precigen (PGEN) Overview: Precigen is a Germantown based biotech developing gene and cell therapies, including cancer immunotherapies and vaccines, using its AdenoVerse and UltraCAR T platforms. Operations: Precigen reports about US$85.7 million from biotechnology startup activities, with roughly US$85.3 million generated in the United States. Market Cap: US$2.7b Precigen matters for this cancer vaccine and immuno-oncology theme because it is already turning its immune based platforms into real-world HPV driven therapies.
"Rapid uptake of PAPZIMEOS in a sizable and previously underserved adult RRP population, combined with strong physician enthusiasm and broad label coverage, supports a multi year ramp in product revenue as pent up demand converts into treated patients." The key factor for Precigen now is how any pressure on future pricing and access may shape the payoff from that early momentum. That pricing risk is only half the story, and the full narrative for Precigen unpacks how Precigen’s immune platforms, capital needs, and competitive position could evolve from here. NasdaqGS:PGEN Revenue & Expenses Breakdown as at Oct 2026 Iovance Biotherapeutics (IOVA) Overview: Iovance Biotherapeutics develops and commercializes personalized tumor infiltrating lymphocyte cell therapies for advanced melanoma and other difficult solid tumors.
Operations: Iovance Biotherapeutics reports about US$325 million from autologous TIL therapies, with roughly US$321 million generated in the United States. Market Cap: US$5.9b Iovance Biotherapeutics matters for this cancer vaccine and immuno-oncology theme because it is a pure-play TIL cell therapy developer already selling an approved solid tumor treatment and building out a broader platform across multiple cancers. "Amtagvi is already approved in the United States and is the first TIL (tumor-infiltrating lymphocyte) therapy available for patients with advanced melanoma." The real swing factor for Iovance now is how one unresolved pressure on its expansion plans shapes future demand and profitability.
That unresolved pressure is exactly what the full narrative for Iovance Biotherapeutics unpacks, showing how Iovance Biotherapeutics could balance expansion risk with accelerating momentum in solid tumor cell therapies. NasdaqGM:IOVA 1-Year Stock Price Chart Immunocore Holdings (IMCR) Overview: Immunocore Holdings develops and sells TCR based immunotherapies such as KIMMTRAK for melanoma, with additional oncology and infectious disease programs. Operations: Immunocore generates about US$430.8 million from immunotherapies, with roughly US$278.7 million in the United States and US$134.1 million in Europe.
Market Cap: US$1.5b Immunocore Holdings provides targeted exposure to the immuno oncology theme because its TCR platform is already in market and is progressing through melanoma trials that could influence how certain patients are treated. "Enrollment in the Phase 3 TEBE-AM trial in previously treated advanced cutaneous melanoma is nearing the target of 540 patients, with top line data expected as early as the end of 2026." The outlook for long term returns from Immunocore’s IO franchise now depends on how one less visible funding and pricing tension is resolved. That funding and pricing question is exactly what the full narrative for Immunocore Holdings unpacks, highlighting where Immunocore Holdings could see returns accelerate or risks quietly build.
NasdaqGS:IMCR Earnings & Revenue History as at Oct 2026 Seeking Alternatives Before Everyone Else? Fresh ideas move first. When new themes catch momentum, the best entry points can fly past while you watch from the sidelines.
Check these curated lists and consider whether they fit your strategy. Spot income workhorses before yields get compressed by new buyers through the curated 8 dividend fortresses . This could help anchor a portfolio when growth stories wobble.
Hunt for quietly compounding operators using the curated list of solid balance sheet and fundamentals (25 results) before balance sheet strength is fully reflected in valuations and the easy rerating window closes. Explore the next leg of automation momentum with the curated 91 robotics and automation stocks while these enablers of efficiency gains are still relatively under the radar. This article by Simply Wall St is general in nature.
We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. New: Manage All Your Stock Portfolios in One Place We've created the ultimate portfolio companion for stock investors, and it's free. • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free Have feedback on this article?
Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Source: Simply Wall Street
